Relationship between Dysphagia and Serum Substance P Level in Chronic Central Nervous Disease

Yoshiyuki Kishida, Naoto Maeda, Yoshikazu Murawaki

Second Department of Internal Medicine, Tottori University School of Medicine, Yonago, Japan.

DOI: 10.4236/ijcm.2013.42016                

Abstract

Purpose: We compared serum substance P (SP) levels in underlying diseases and dysphagia, or its absence, in patients with cerebrovascular disease, neurodegenerative disease or Alzheimer’s disease, to investigate the relationship between dysphagia and serum SP in chronic central nervous disease. Methods: Subjects comprised 94 patients admitted to a hospital or nursing home during the 5 years between April 2007 and April 2012 with central nervous symptoms. Serum SP levels were measured by enzyme immunoassay, and video endoscopy using a nasal endoscope in all subjects to objectively evaluate swallowing function. Results: Serum SP level was very similar in central nervous disease without dysphagia and controls without central nervous disease. Conversely, serum SP level was significantly lower in central nervous disease with dysphagia. When comparing underlying diseases, serum SP was significantly lower in Parkinson’s disease than in other disease groups (cerebrovascular disease, Alzheimer’s disease). Looking at changes in serum SP levels over time after disease onset, SP level was significantly low in subjects without dysphagia at the time of onset who went on to develop dysphagia during the disease course, whereas serum SP level tended to be higher in subjects with dysphagia at the time of onset and improvement during the disease course. With Parkinson’s disease and cerebrovascular disease, serum SP was low, particularly in subjects thought to have severe damage to the basal ganglia. Conclusion: Serum SP is generally thought to decrease in patients with cerebrovascular disease accompanied by dysphagia, but these results suggest that serum SP levels can be expected to improve to some extent, even if dysphagia is present at disease onset, assuming, for example, that some basal ganglia function remains. Positive therapeutic interventions such as swallowing rehabilitation should be promoted in such patients, with the goal of improving swallowing function.

Keywords

Substance P; Dysphagia; Central Nervous Disease

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	[1] S. Teramoto, Y. Fukuchi, H. Sasaki, K. Sato, K. Seki zawa and T. Matsuse, “High Incidence of Aspiration Pneumonia in Community and Hospital Acquired Pneu monia in Hospitalized Patients: A Multicenter, Prospec tive Study in Japan.” Journal of the American Geriatrics Society, Vol. 56, No. 3, 2008, pp. 577 579. doi:10.1111/j.1532 5415.2008.01597.x
[2]	M. Yamawaki, “Prevalence of Aspration Pneumonia,” Sogo Riha., Vol. 37, 2009, pp. 105 109.
[3]	T. Nakagawa, T. Ohrui, K. Sekizawa and H. Sasaki, “Sputum Substance P in Aspiration Pneumonia,” Lancet, Vol. 345, No. 8962, 1995, p. 1447. doi:10.1016/S0140 6736(95)92638 0
[4]	T. Nakagawa, K. Sekizawa, H. Arai, R. Kikuchi, K. Ma nabe and H. Sasaki, “High Incidence of Pneumonia in Elderly Patients with Basal Ganglia Infarction,” Arch In ternational Medicine, Vol. 157, No. 3, 1997, pp. 321 324. doi:10.1001/archinte.1997.00440240085013
[5]	Y. S. Lee, K. M. Km, C. Shin, J. J. Shim, K. H. Kim, H. K. Kang, H. S. Yoo and H. K. In, “Substance P Immu noreactive Nerves in Endobronchial Biopsies in Cough Variant Asthma and Classic Asthma,” Respiration, Vol. 70, No. 1, 2003, pp. 49 53. doi:10.1159/000068413
[6]	T. Nagamine, “Serum Substance P Levels in Patients with Chronic Schizophrenia Treated with Typical or Atypical Antipsychotics,” Neuropsychiatric Disease and Treat ment, Vol. 4, No. 1, 2008, pp. 289 294. doi:10.2147/NDT.S2367
[7]	S. Matsumoto, S. Shimodo and K. Kawahira, “Substance P,” Geriatric Medicine, Vol. 45, 2007, pp. 1331 1335.
[8]	Y. Jin, K. Sekizawa, T. Fukushima, M. Morikawa, H. Nakazawa and H. Sasaki, “Capsaicin Desensitization Im hibits Swallowing Reflex in Guinea Pigs,” American Journal of Respiratory and Critical Care Medicine, Vol. 149, No. 1, 1994, pp. 261 263.
[9]	D. Ramsey, D. Smithard and L. Kalra, “Silent Aspration: What Do We Know?” Dysphgia Vol. 20, No. 3, 2005, pp. 218 225. doi:10.1007/s00455 005 0018 9
[10]	T. Kisa, Rinsyoueiyou, Vol. 106, 2005, pp. 327 333.
[11]	S. Teramoto, “Aspration Pneumonia May Not Be Pre vented by Gastrostmyalone,” Journal of Clinical Reha bilitation, Vol. 17, 2008, pp. 826 829